



Neuren (NEU) – ASX Announcement

27 February 2025

Neuren 2024 results investor webinar on 28 February 2025

Investor Webinar | Friday, 28 Feb 2025 at 12.30 PM AEDT

You are invited to register using this link:

https://us06web.zoom.us/webinar/register/WN_R_Xh9A3SaCXTqBuqUVyyw

Participants may submit questions at registration or during the session

Thursday 27 February 2025, Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU), following today's confirmation of the DAYBUE™ (trofinetide) royalty in Q4 2024 for inclusion in its audited financial statements, will report its full-year 2024 financial results on Friday 28 February 2025 and Neuren's management will host an investor webinar at 12:30 Australian Eastern Daylight Time to discuss the results. Registration for the webinar may be completed via the link above.

About Neuren

Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, all programs have been granted "orphan drug" designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.

DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) and Health Canada for the treatment of Rett syndrome. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide.

Neuren's second drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome.

Contact:

investorrelations@neurenpharma.com

Jon Pilcher, CEO: +61 438 422 271

ASX Listing Rules information

This announcement was authorized to be given to the ASX by the CEO & Managing Director of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124

Forward-looking Statements

This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.